Skip to main content

Abbvie Inc(ABBV-N)

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303 - Tue Mar 5, 6:00AM CST

This is the eighth drug using Dragonfly's platform technology, and the sixth TriNKET® to enter into clinical trials.

WALTHAM, Mass., March 5, 2024 /CNW/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced receipt of a milestone payment following dosing of the first patient in a clinical trial conducted by AbbVie (NYSE: ABBV) to evaluate ABBV-303, a solid tumor targeting TriNKET®.


Provided Content: Content provided by The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe